Daily Archives

January 10, 2019

Home / January 10, 2019

Pain Management Task Force Calls for Patient-Centered Treatment of Pain

The HHS Pain Management Best Practices Inter-Agency Task Force has released a draft report calling for individualized, patient-centered pain management to improve the lives of millions of individuals who experience acute and chronic pain. Members of the public have 90 days to provide comments on the report’s recommendations. The Academy is preparing comments and encourages members to provide input as individuals as well. Read about the draft report.

KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ®

 KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for two additional strengths of APADAZ®, an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP). The approval of these new dosage strengths, 4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP, follows the New Drug Application (NDA) approval on February 23, 2018 of the 6.12 mg benzhydrocodone/325 mg APAP dosage strength of APADAZ. Full story.

1 2 3
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.
AAPM

American Academy of Pain Medicine